Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24737027 | 0.85 | CACNA1H (0.36) | CACNA1HEPHA2KDREPHB4DRD4 | |
| SCHEMBL24170859 | 0.83 | CACNA1H (0.35) | CACNA1HEPHA2KDREPHB4DRD4 | |
| SCHEMBL12395723 | 0.83 | HRH3 (0.39) | CACNA1HDRD4 | |
| SCHEMBL24774773 | 0.82 | CACNA1H (0.40) | CACNA1HEPHA2KDREPHB4DRD4 | |
| SCHEMBL24775467 | 0.81 | CACNA1H (0.34) | CACNA1HDRD4 | |
| SCHEMBL23323124 | 0.80 | CACNA1H (0.33) | CACNA1HEPHA2KDREPHB4DRD4 | |
| SCHEMBL25743385 | 0.79 | CACNA1H (0.34) | CACNA1HDRD4 | |
| SCHEMBL24171110 | 0.79 | HDAC1 (0.39) | CACNA1H | |
| SCHEMBL24171103 | 0.79 | HDAC1 (0.39) | CACNA1H | |
| SCHEMBL12257331 | 0.79 | HDAC1 (0.39) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | CACNA1H 4449/4885EPHA2 3104/4885KDR 2040/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | CACNA1H 2903/4885EPHA2 4076/4885KDR 2792/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | CACNA1H 4449/4885EPHA2 3104/4885KDR 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.